Axiom ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4515-SKC3

Klow · Lot 926-Kl-80
Issued Sep 6, 2026 · v1
Verify: 6975-91DD-1490

SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

4 of 4 layers complete

L1	L2	L3	L4
Identity	Purity	Net Peptide Content	Sterility

Sample & Vial Validation



Vial A: as received & analyzed

Client	**AncientCity Biotech**	Product	**Klow**
Lot / Batch	**926-Kl-80**	Label Claim	**80 mg**
Matrix	**lyophilized powder**	Sample Count	**1**
Vial Size	**3mL**	Cap Color	**Blue**
Crimp Color	**Silver / Aluminum**	Contents Color	**Blue**
Seal Intact	**Yes**	Condition	**sealed, intact**
Received	**Sep 2, 2026**	Sampling	**client submitted**

Test Results

Test	Reference standard	Result	
Identity	every declared component within ±1 Da of its own theoretical mass	`4 of 4 components confirmed`	PASS
Purity	each declared component at or above its own locked purity criterion	`4 of 4 components within criterion`	PASS
Net Peptide Content	each declared component within its own locked content criterion, at the declared ratio	`82.7 mg of 80 mg declared (+3.4%), 4 of 4 components within criterion`	PASS
Sterility · Rapid PCR	Rapid PCR screen	`Target DNA not detected`	PASS

Layer Results

1 Identity

HILIC-ESI-MS intact GHK-Cu full-scan/isotope identity + LC-MS/MS (ESI+) accurate mass

4 of 4 components confirmed
each +/- 1 Da of its component mass

PASS

Component	Its criterion	Observed	Status
GHK-Cu	402.92 Da · acceptance ±1 Da · average	`402.92 Da`	PASS
BPC-157	1419.556 Da · acceptance ±1 Da · average	`1419.556 Da`	PASS
TB-500 (Thymosin B4)	4963.506 Da · acceptance ±1 Da · average	`4963.506 Da`	PASS
KPV	342.44 Da · acceptance ±1 Da · average	`342.44 Da`	PASS

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4515-SKC3

Klow · Lot 926-Kl-80
Issued Sep 6, 2026 · v1
Verify: 6975-91DD-1490

SCAN TO VERIFY

2 Purity

HILIC-CAD homogeneity (universal detection) + RP-HPLC 214 nm area% (USP <621>)

4 of 4 components within criterion
each component at or above its own locked purity criterion

PASS

Component	Its criterion	Observed	Status
GHK-Cu	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.96%	PASS
BPC-157	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.97%	PASS
TB-500 (Thymosin B4)	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.99%	PASS
KPV	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.94%	PASS

3 Net Peptide Content

Quantitative HPLC vs reference std

82.7 mg of 80 mg declared (+3.4%), 4 of 4 components within criterion
each component within its own locked content criterion, at the declared ratio

PASS

Component	Its criterion	Observed	Status
GHK-Cu	5 parts · 45–55 mg · Declared blend recipe on the controlled Axiom catalog record for Klow (component ratio 5); acceptance ±10% per Axiom SPEC-CONTENT-001	51.32 mg	PASS
BPC-157	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for Klow (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001	10.57 mg	PASS
TB-500 (Thymosin B4)	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for Klow (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001	10.63 mg	PASS
KPV	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for Klow (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001	10.18 mg	PASS

Observed ratio **GHK-Cu 4.86 : BPC-157 1.00 : TB-500 (Thymosin B4) 1.01 : KPV 0.96** against declared **GHK-Cu 5.00 : BPC-157 1.00 : TB-500 (Thymosin B4) 1.00 : KPV 1.00** · source Declared blend recipe on the controlled Axiom catalog record for Klow (component ratio 5); acceptance ±10% per Axiom SPEC-CONTENT-001

4 Sterility

Rapid Microbial DNA Screen — Qualification-Bound Target Panel

Sterility · Rapid PCR: No Growth
No microbial growth or target DNA detected

PASS

Sterility · Rapid PCR PASS

Result		Specification	
	No Growth		**Rapid PCR screen**

Reporting Scope & Limitations

`[Purity]` The chromatographic trace was not retained for this certificate. The purity value and its acceptance limit are unaffected.

`[Identity]` The mass spectrum was not retained for this certificate. Identity is reported from the recorded accurate mass against its theoretical value.

`[Sterility · Rapid PCR]` DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4515-SKC3

Klow · Lot 926-Kl-80
Issued Sep 6, 2026 · v1
Verify: 6975-91DD-1490

SCAN TO VERIFY

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:02970c648042af6d35707613...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:77bb2ab5aba8be01e5d6b9cb...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:c044dd25f0f49bc8d9e7ccd1...**

Physical instrument analysis is performed at Axiom Analytics' discretion (based on method, capacity, and order volume), either in Axiom's own laboratory under its documented quality system or by an independent partner laboratory engaged under confidentiality. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: samples are analyzed under double-blind conditions, identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at https://axiomanalyticslab.com/verify/AX-2026-4515-SKC3.

✓ **CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)**

SHA-384: 8e1466ff1a122bb83aeb1bc3690d23143ee640d1678bd7f0a84a43610215d5bd...

Seal: ed25519:b89e1eca11cabf1cd2ef7840b6fc740c00b27e31...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.